NeuroPace Raises $67M To Help Commercialize RNS System For Epilepsy
Executive Summary
The latest financing round will also support a new clinical trial of the RNS system for children with epilepsy.
You may also be interested in...
NeuroPace Seeks $75M In IPO
The California neuromodulation company filed a registration with the US Securities and Exchange Commission to sell common stock on NASDAQ under the ticker NPCE.
NeuroPace’s RNS For Epilepsy Becomes First FDA-Approved Responsive Neurostimulator
While standard neurostimulators are open-loop systems that stimulate continuously or intermittently according to preprogramming, RNS is a more targeted, closed-loop system that monitors brain activity in real time and provides electrical stimulation to interrupt troubling patterns that might cause a seizure.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.